Engineering varied serine protease inhibitors by converting P1 site of BF9, a weakly active Kunitz-type animal toxin

International Journal of Biological Macromolecules
Li DingZongyun Chen

Abstract

Although there were a lot of weakly active animal toxins in the venoms, their values and applications are still mysterious, such as BF9, which is a Kunitz-type toxin isolated from the venom of the elapid snake Bungarus fasciatus. Here, we used BF9 to be a molecular scaffold, and engineered eight BF9-derived peptides by changing P1 site Asn17 of BF9, such as BF9-N17Y and BF9-N17T designed from the polar subfamily, BF9-N17L and BF9-N17G designed from the Non-polar subfamily, BF9-N17D designed from acidic subfamily, and BF9-N17H, BF9-N17K and BF9-N17R designed from basic subfamily. Through enzyme inhibitor experiment assays, we found a potent and selective chymotrypsin inhibitor BF9-N17Y, a potent and selective coagulation factor XIa inhibitor BF9-N17H, and two highly potent coagulation factor XIa inhibitors BF9-N17K and BF9-N17. APTT and PT assays further showed that BF9-N17H, BF9-N17K and BF9-N17R were three novel anticoagulants with selectively intrinsic coagulation pathway inhibitory activity. Considering that natural weakly active animal toxins are also a huge peptide resource, our present work might open a new window about pharmacological applications of weakly active animal toxins, which might be good templates for potent a...Continue Reading

References

Aug 16, 2000·Thrombosis Research·A V Pokhilko
Dec 17, 2003·The Biochemical Journal·Stéphanie MouhatJean-Marc Sabatier
Aug 1, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Lior CohenDalia Gordon
Mar 29, 2007·Journal of Thrombosis and Haemostasis : JTH·D Gailani, T Renné
Oct 6, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·David Gailani, Thomas Renné
Dec 25, 2007·The Journal of Pharmacology and Experimental Therapeutics·Michel DemeuleRichard Béliveau
Oct 17, 2008·PloS One·Chun-Hua YuanSong-Ping Liang
Nov 4, 2008·Cellular and Molecular Life Sciences : CMLS·L St PierreM F Lavin
Jul 31, 2009·Annual Review of Genomics and Human Genetics·Bryan G FryRicardo C Rodríguez de la Vega
Sep 20, 2012·Nature Communications·Nicholas R CasewellWolfgang Wüster
Jun 5, 2013·Proceedings of the National Academy of Sciences of the United States of America·Sanjeev Kumar UpadhyayK George Chandy
Jun 19, 2013·Marine Drugs·Caroline B F Mourão, Elisabeth F Schwartz
Dec 20, 2013·Toxins·Timothy N W JacksonBryan G Fry
Aug 5, 2014·Journal of Molecular Biology·Jeet KaliaFrank Bosmans
Dec 17, 2015·Pharmacological Reviews·Barbara MulloyClive P Page
Jul 5, 2016·Thrombosis Research·Brian C Cooley
Sep 18, 2016·Hematology/oncology Clinics of North America·Allison P Wheeler, David Gailani
Feb 11, 2018·Cellular and Molecular Life Sciences : CMLS·Andrew A WalkerGlenn F King

❮ Previous
Next ❯

Citations

Apr 4, 2021·International Journal of Molecular Sciences·Vincent MariauleMoez Rhimi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.